Sagimet Biosciences Inc.
SGMTNext catalyst
Denifanstat
Acne Vulgaris
Get an email about SGMT's next catalysts
Track Sagimet Biosciences (SGMT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
SGMT Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.25 | FQ end Sep/2026 | Call: tbd
Denifanstat Phase 3 Est. Readout
Estimated primary completion for Denifanstat trial (NCT07863193) in Acne Vulgaris. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Denifanstat
Acne Vulgaris
TVB-2640 (US)
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
TVB-2640
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
3-V Bioscience-2640
Metabolic Syndrome
TVB-2640 (China)
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Denifanstat | Phase 3 | Acne Vulgaris | - | - |
TVB-2640 (US) | Phase 2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | - | - |
TVB-2640 | Phase 2 | Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease | - | - |
3-V Bioscience-2640 | Phase 2 | Metabolic Syndrome | - | - |
TVB-2640 (China) | Phase 2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | - | - |
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
2 drugs in this indication
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Sagimet Biosciences Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Sagimet Biosciences Inc.'s (SGMT) pipeline across Phase 3, Phase 2. Its lead program is Denifanstat (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sagimet Biosciences Inc.'s next FDA catalyst?→
Sagimet Biosciences Inc.'s (SGMT) next tracked catalyst is a Phase 3 readout expected August 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SGMT biotech catalysts?→
Add SGMT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sagimet Biosciences Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.